Some good news about a vaccine test (though it's still early)

Some good news about a vaccine test (though it's still early)

Moderna is worth watching, but not only for good reasons. The company and public health officials will need to evaluate all the data before making the vaccine publicly available.

But before we all start making our plans for what we will do after we have a safe vaccine, it is important to take these results with a grain of salt. Here are a few reasons why.

In upcoming phases of the trial, researchers will be trying to strike a balance around the effectiveness of the vaccine at lower doses - because the lowest effective dose will allow for greater production volume when the time comes.

A view of Moderna headquarters on May 08, 2020 in Cambridge, Massachusetts.

NIAID doesn't hide its light under a bushel.

Moderna did not immediately respond to a Reuters' request for comment. "This was a press release that talked about eight participants in two groups each receiving two doses of the vaccine - either 25 micrograms or 100 micrograms - and it's an interim report".

"The really nice thing about this vaccine, compared to other vaccines, is that it's not a live virus", Manning said.

Critically, eight of them had produced "neutralising" antibodies - the ones that confer the greatest protection. Testing for neutralizing antibodies is more time-consuming than other antibody tests and must be done in a biosecurity level 3 laboratory.

Nevertheless, Stat said that was "still a reason for caution". As for the third group, the ones given the highest dose of the mRNA vaccine, no data has been released yet regarding the second dose. The participants were then given a second dose about a month later. So the best-case scenario is that the vaccine for the novel coronavirus which has caused this worldwide pandemic might have a vaccine this year or early 2021. When measured, the levels of their antibodies were found to be similar to those of people who had recovered from the disease.

Immunogenicity means the ability of the vaccine to induce an immune response in participants.

STAT asked Moderna for information on the antibody levels it used as a comparator.

Stock in Moderna finished the regular session down by 10.41% to $71.67 and as of 2130 GMT were falling by 5.46% to $67.67 in after-hours trading.

The company's vaccine could be ready for emergency use as early as the fall, if it proves to work safely in the subsequent testing. The vaccine looks safe, and volunteers developed antibodies. That's not enough to generate confidence within the scientific community.

There is no proven treatment or vaccine against the coronavirus at this time. "They have not published any of that".

"I would like to see the data to make my own interpretation of the data".

Unlike a normal vaccine, which is supposed to train up the body's immune system to recognize and resist a virus, RNA vaccines are designed or coded to tell cells what to build to resist certain diseases.

Another open question is how durable and long-lasting the neutralizing-antibody response is from Moderna's vaccine, Raffat said. The American firm has already started trial on humans in the United States in phase 1 and phase 2 of its vaccine programme.

Related Articles